Related Announcements

RFA-CA-22-003 - Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)

Issued by

National Cancer Institute (NCI)

Purpose

The purpose of this Notice is to inform the applicant community of a change in the page limitation for the Research Strategy section for applications submitted to Funding Opportunity Announcement (FOA) RFA-CA-22-003 - Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed).

The following section of RFA-CA-22-003 has been amended:

Currently Reads:

Section IV. Application and Submission Information

2. Content and Form of Application Submission

Page Limitations

All page limitations described in the SF424 Application Guide and the Table of Page Limits must be followed.

Modified to Read (changes shown in bold italics):

Section IV. Application and Submission Information

2. Content and Form of Application Submission

Page Limitations

All page limitations described in the SF424 Application Guide and the Table of Page Limits must be followed. For this specific FOA, the Research Strategy section is limited to 6 pages.

All other aspects of this FOA remain the same.

Inquiries

Please direct all inquiries to:

Tony Dickherber, Ph.D.
National Cancer Institute (NCI)
Telephone: 301-547-9980
Email: [email protected]